menu
    • menu

    Company profile for ENB Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restori...
    ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ENB TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Alexandria Center For Life Sciences, LaunchLabs 430 E. 29th St., 14th flr New ...
    Telephone
    Telephone
    (212)792-2317
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://enbpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enb-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Coherus, CRI Combo Trial For Ovarian Cancer Treatment
    Coherus, CRI Combo Trial For Ovarian Cancer Treatment

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877879/33333/en/Coherus-Announces-Clinical-Collaboration-with-the-Cancer-Research-Institute-for-a-Novel-Combination-Evaluating-LOQTORZI-toripalimab-tpzi-with-ENB-Therapeutics-ENB-003-for-the-Treat.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study
    ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study

    07 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231107964841/en

    BUSINESSWIRE
    07 Nov 2023
    Share Share
    ENB Presents Results from Ph 1b ENBOLDEN-101 Study in Solid Tumors Refractory
    ENB Presents Results from Ph 1b ENBOLDEN-101 Study in Solid Tumors Refractory

    18 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230717370427/en

    BUSINESSWIRE
    18 Jul 2023
    Share Share
    ENB Therapeutics to present at the 2023 Immuno-Oncology 360o Conferences
    ENB Therapeutics to present at the 2023 Immuno-Oncology 360o Conferences

    24 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230124005106/en

    BUSINESSWIRE
    24 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search